Cubist Pharmaceuticals Inc (CBST) Financial Statements (2023 and earlier)

Company Profile

Business Address 65 HAYDEN AVENUE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments976,229
Cash and cash equivalents104,041
Short-term investments872,188
Receivables93,467
Inventory, net of allowances, customer advances and progress billings41,947
Inventory41,947
Prepaid expense and other current assets31,217
Deferred tax assets 
Other undisclosed current assets14,190
Total current assets:1,157,050
Noncurrent Assets
Property, plant and equipment166,465
Long-term investments and receivables 3,167
Long-term investments 3,167
Intangible assets, net (including goodwill)266,960
Goodwill114,130
Intangible assets, net (excluding goodwill)152,830
Other noncurrent assets
Prepaid expense and other noncurrent assets66,043
Other undisclosed noncurrent assets272,700
Total noncurrent assets:775,335
TOTAL ASSETS:1,932,385
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities209,236
Accounts payable45,603
Accrued liabilities163,633
Deferred revenue and credits6,784
Other liabilities3,500
Other undisclosed current liabilities38,998
Total current liabilities:258,518
Noncurrent Liabilities
Long-term debt and lease obligation466,000
Long-term debt, excluding current maturities466,000
Liabilities, other than long-term debt178,993
Deferred revenue and credits34,091
Deferred tax liabilities, net103,081
Liability for uncertainty in income taxes13,900
Other liabilities27,921
Other undisclosed noncurrent liabilities38,126
Total noncurrent liabilities:683,119
Total liabilities:941,637
Equity
Equity, attributable to parent990,748
Common stock65
Additional paid in capital940,969
Accumulated other comprehensive income (loss)(59)
Retained earnings49,773
Total equity:990,748
TOTAL LIABILITIES AND EQUITY:1,932,385

Income Statement (P&L) ($ in thousands)

12/31/2013
12/31/2012
Revenues926,359
Cost of revenue
(Cost of Goods and Services Sold)
(230,057)
Gross profit:696,302
Operating expenses(511,088)
Other undisclosed operating income51,892
Operating income:237,106
Nonoperating expense(37,510)
Other nonoperating expense(7,595)
Interest and debt expense(32,991)
Other undisclosed income from continuing operations before equity method investments, income taxes32,991
Income (loss) from continuing operations before income taxes:199,596
Income tax expense (benefit)(45,521)
Income (loss) from continuing operations:154,075
Income (loss) before gain (loss) on sale of properties:154,075
Net income (loss) available to common stockholders, basic:154,075
Other undisclosed net income available to common stockholders, diluted 16,729
Net income (loss) available to common stockholders, diluted:170,804

Comprehensive Income ($ in thousands)

12/31/2013
12/31/2012
Net income (loss):154,075
Comprehensive income (loss):154,075
Other undisclosed comprehensive income, net of tax, attributable to parent126
Comprehensive income (loss), net of tax, attributable to parent:154,201

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: